10:23 AM EST - Prometic Life Sciences Inc. : Announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to its Inter-Alpha-Inhibitor-Proteins for the treatment of Necrotizing Enterocolitis. In addition to the Rare Pediatric Disease Designation, IAIP has also been granted an Orphan Drug Designation by the FDA. Prometic Life Sciences Inc.
shares T.PLI are trading up $0.08 at $1.46.
